Report cover image

Global Factor Xa Inhibitors Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 219 Pages
SKU # APRC20279702

Description

Summary

According to APO Research, the global Factor Xa Inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Factor Xa Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Factor Xa Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Factor Xa Inhibitors market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Factor Xa Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Factor Xa Inhibitors market include Chia Tai Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Ouyi Pharmaceutical, Qilu Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Shanghai Huilun Pharmaceutical and Hansoh Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Factor Xa Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Factor Xa Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Factor Xa Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Factor Xa Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Factor Xa Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Factor Xa Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Factor Xa Inhibitors Segment by Company

Chia Tai Tianqing Pharmaceutical
Zhejiang Hisun Pharmaceutical
Cspc Ouyi Pharmaceutical
Qilu Pharmaceutical
Nanjing King-Friend Biochemical Pharmaceutical
Kelun Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Shanghai Huilun Pharmaceutical
Hansoh Pharma
HEC Pharma
BrightGene
Zydus
Viatris
Pfizer
Lupin
Janssen Pharmaceuticals
GlaxoSmithKline
Eugia Pharma
Dr. Reddy's Laboratories
Daiichi Sankyo
Bristol Myers Squibb
Bayer
Apotex
Accord Healthcare
Factor Xa Inhibitors Segment by Type

Oral Drugs
Injections
Factor Xa Inhibitors Segment by Application

Atrial Fibrillation
Deep Vein Thrombosis
Pulmonary Embolism
Other
Factor Xa Inhibitors Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Factor Xa Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Factor Xa Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Factor Xa Inhibitors significant trends, drivers, influence factors in global and regions.
6. To analyze Factor Xa Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Factor Xa Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Factor Xa Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Factor Xa Inhibitors industry.
Chapter 3: Detailed analysis of Factor Xa Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Factor Xa Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

219 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Factor Xa Inhibitors Sales Value (2020-2031)
1.2.2 Global Factor Xa Inhibitors Sales Volume (2020-2031)
1.2.3 Global Factor Xa Inhibitors Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Factor Xa Inhibitors Market Dynamics
2.1 Factor Xa Inhibitors Industry Trends
2.2 Factor Xa Inhibitors Industry Drivers
2.3 Factor Xa Inhibitors Industry Opportunities and Challenges
2.4 Factor Xa Inhibitors Industry Restraints
3 Factor Xa Inhibitors Market by Company
3.1 Global Factor Xa Inhibitors Company Revenue Ranking in 2024
3.2 Global Factor Xa Inhibitors Revenue by Company (2020-2025)
3.3 Global Factor Xa Inhibitors Sales Volume by Company (2020-2025)
3.4 Global Factor Xa Inhibitors Average Price by Company (2020-2025)
3.5 Global Factor Xa Inhibitors Company Ranking (2023-2025)
3.6 Global Factor Xa Inhibitors Company Manufacturing Base and Headquarters
3.7 Global Factor Xa Inhibitors Company Product Type and Application
3.8 Global Factor Xa Inhibitors Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Factor Xa Inhibitors Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Factor Xa Inhibitors Market by Type
4.1 Factor Xa Inhibitors Type Introduction
4.1.1 Oral Drugs
4.1.2 Injections
4.2 Global Factor Xa Inhibitors Sales Volume by Type
4.2.1 Global Factor Xa Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Factor Xa Inhibitors Sales Volume by Type (2020-2031)
4.2.3 Global Factor Xa Inhibitors Sales Volume Share by Type (2020-2031)
4.3 Global Factor Xa Inhibitors Sales Value by Type
4.3.1 Global Factor Xa Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Factor Xa Inhibitors Sales Value by Type (2020-2031)
4.3.3 Global Factor Xa Inhibitors Sales Value Share by Type (2020-2031)
5 Factor Xa Inhibitors Market by Application
5.1 Factor Xa Inhibitors Application Introduction
5.1.1 Atrial Fibrillation
5.1.2 Deep Vein Thrombosis
5.1.3 Pulmonary Embolism
5.1.4 Other
5.2 Global Factor Xa Inhibitors Sales Volume by Application
5.2.1 Global Factor Xa Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Factor Xa Inhibitors Sales Volume by Application (2020-2031)
5.2.3 Global Factor Xa Inhibitors Sales Volume Share by Application (2020-2031)
5.3 Global Factor Xa Inhibitors Sales Value by Application
5.3.1 Global Factor Xa Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Factor Xa Inhibitors Sales Value by Application (2020-2031)
5.3.3 Global Factor Xa Inhibitors Sales Value Share by Application (2020-2031)
6 Factor Xa Inhibitors Regional Sales and Value Analysis
6.1 Global Factor Xa Inhibitors Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Factor Xa Inhibitors Sales by Region (2020-2031)
6.2.1 Global Factor Xa Inhibitors Sales by Region: 2020-2025
6.2.2 Global Factor Xa Inhibitors Sales by Region (2026-2031)
6.3 Global Factor Xa Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Factor Xa Inhibitors Sales Value by Region (2020-2031)
6.4.1 Global Factor Xa Inhibitors Sales Value by Region: 2020-2025
6.4.2 Global Factor Xa Inhibitors Sales Value by Region (2026-2031)
6.5 Global Factor Xa Inhibitors Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Factor Xa Inhibitors Sales Value (2020-2031)
6.6.2 North America Factor Xa Inhibitors Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Factor Xa Inhibitors Sales Value (2020-2031)
6.7.2 Europe Factor Xa Inhibitors Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Factor Xa Inhibitors Sales Value (2020-2031)
6.8.2 Asia-Pacific Factor Xa Inhibitors Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Factor Xa Inhibitors Sales Value (2020-2031)
6.9.2 South America Factor Xa Inhibitors Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Factor Xa Inhibitors Sales Value (2020-2031)
6.10.2 Middle East & Africa Factor Xa Inhibitors Sales Value Share by Country, 2024 VS 2031
7 Factor Xa Inhibitors Country-level Sales and Value Analysis
7.1 Global Factor Xa Inhibitors Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Factor Xa Inhibitors Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Factor Xa Inhibitors Sales by Country (2020-2031)
7.3.1 Global Factor Xa Inhibitors Sales by Country (2020-2025)
7.3.2 Global Factor Xa Inhibitors Sales by Country (2026-2031)
7.4 Global Factor Xa Inhibitors Sales Value by Country (2020-2031)
7.4.1 Global Factor Xa Inhibitors Sales Value by Country (2020-2025)
7.4.2 Global Factor Xa Inhibitors Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.5.2 USA Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.6.2 Canada Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.8.2 Germany Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.9.2 France Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.9.3 France Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.11.2 Italy Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.12.2 Spain Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.13.2 Russia Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.16.2 China Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.16.3 China Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.17.2 Japan Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.19.2 India Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.19.3 India Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.20.2 Australia Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.24.2 Chile Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.26.2 Peru Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.28.2 Israel Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.29.2 UAE Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.31.2 Iran Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Factor Xa Inhibitors Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Factor Xa Inhibitors Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Factor Xa Inhibitors Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Chia Tai Tianqing Pharmaceutical
8.1.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.1.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.1.4 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8.2 Zhejiang Hisun Pharmaceutical
8.2.1 Zhejiang Hisun Pharmaceutical Comapny Information
8.2.2 Zhejiang Hisun Pharmaceutical Business Overview
8.2.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.2.4 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.2.5 Zhejiang Hisun Pharmaceutical Recent Developments
8.3 Cspc Ouyi Pharmaceutical
8.3.1 Cspc Ouyi Pharmaceutical Comapny Information
8.3.2 Cspc Ouyi Pharmaceutical Business Overview
8.3.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.3.4 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.3.5 Cspc Ouyi Pharmaceutical Recent Developments
8.4 Qilu Pharmaceutical
8.4.1 Qilu Pharmaceutical Comapny Information
8.4.2 Qilu Pharmaceutical Business Overview
8.4.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.4.4 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.4.5 Qilu Pharmaceutical Recent Developments
8.5 Nanjing King-Friend Biochemical Pharmaceutical
8.5.1 Nanjing King-Friend Biochemical Pharmaceutical Comapny Information
8.5.2 Nanjing King-Friend Biochemical Pharmaceutical Business Overview
8.5.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.5.4 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.5.5 Nanjing King-Friend Biochemical Pharmaceutical Recent Developments
8.6 Kelun Pharmaceutical
8.6.1 Kelun Pharmaceutical Comapny Information
8.6.2 Kelun Pharmaceutical Business Overview
8.6.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.6.4 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.6.5 Kelun Pharmaceutical Recent Developments
8.7 Jiangsu Hengrui Pharmaceuticals
8.7.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
8.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
8.7.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.7.4 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio
8.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
8.8 Shanghai Huilun Pharmaceutical
8.8.1 Shanghai Huilun Pharmaceutical Comapny Information
8.8.2 Shanghai Huilun Pharmaceutical Business Overview
8.8.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.8.4 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio
8.8.5 Shanghai Huilun Pharmaceutical Recent Developments
8.9 Hansoh Pharma
8.9.1 Hansoh Pharma Comapny Information
8.9.2 Hansoh Pharma Business Overview
8.9.3 Hansoh Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.9.4 Hansoh Pharma Factor Xa Inhibitors Product Portfolio
8.9.5 Hansoh Pharma Recent Developments
8.10 HEC Pharma
8.10.1 HEC Pharma Comapny Information
8.10.2 HEC Pharma Business Overview
8.10.3 HEC Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.10.4 HEC Pharma Factor Xa Inhibitors Product Portfolio
8.10.5 HEC Pharma Recent Developments
8.11 BrightGene
8.11.1 BrightGene Comapny Information
8.11.2 BrightGene Business Overview
8.11.3 BrightGene Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.11.4 BrightGene Factor Xa Inhibitors Product Portfolio
8.11.5 BrightGene Recent Developments
8.12 Zydus
8.12.1 Zydus Comapny Information
8.12.2 Zydus Business Overview
8.12.3 Zydus Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.12.4 Zydus Factor Xa Inhibitors Product Portfolio
8.12.5 Zydus Recent Developments
8.13 Viatris
8.13.1 Viatris Comapny Information
8.13.2 Viatris Business Overview
8.13.3 Viatris Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.13.4 Viatris Factor Xa Inhibitors Product Portfolio
8.13.5 Viatris Recent Developments
8.14 Pfizer
8.14.1 Pfizer Comapny Information
8.14.2 Pfizer Business Overview
8.14.3 Pfizer Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.14.4 Pfizer Factor Xa Inhibitors Product Portfolio
8.14.5 Pfizer Recent Developments
8.15 Lupin
8.15.1 Lupin Comapny Information
8.15.2 Lupin Business Overview
8.15.3 Lupin Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.15.4 Lupin Factor Xa Inhibitors Product Portfolio
8.15.5 Lupin Recent Developments
8.16 Janssen Pharmaceuticals
8.16.1 Janssen Pharmaceuticals Comapny Information
8.16.2 Janssen Pharmaceuticals Business Overview
8.16.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.16.4 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio
8.16.5 Janssen Pharmaceuticals Recent Developments
8.17 GlaxoSmithKline
8.17.1 GlaxoSmithKline Comapny Information
8.17.2 GlaxoSmithKline Business Overview
8.17.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.17.4 GlaxoSmithKline Factor Xa Inhibitors Product Portfolio
8.17.5 GlaxoSmithKline Recent Developments
8.18 Eugia Pharma
8.18.1 Eugia Pharma Comapny Information
8.18.2 Eugia Pharma Business Overview
8.18.3 Eugia Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.18.4 Eugia Pharma Factor Xa Inhibitors Product Portfolio
8.18.5 Eugia Pharma Recent Developments
8.19 Dr. Reddy's Laboratories
8.19.1 Dr. Reddy's Laboratories Comapny Information
8.19.2 Dr. Reddy's Laboratories Business Overview
8.19.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.19.4 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio
8.19.5 Dr. Reddy's Laboratories Recent Developments
8.20 Daiichi Sankyo
8.20.1 Daiichi Sankyo Comapny Information
8.20.2 Daiichi Sankyo Business Overview
8.20.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.20.4 Daiichi Sankyo Factor Xa Inhibitors Product Portfolio
8.20.5 Daiichi Sankyo Recent Developments
8.21 Bristol Myers Squibb
8.21.1 Bristol Myers Squibb Comapny Information
8.21.2 Bristol Myers Squibb Business Overview
8.21.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.21.4 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio
8.21.5 Bristol Myers Squibb Recent Developments
8.22 Bayer
8.22.1 Bayer Comapny Information
8.22.2 Bayer Business Overview
8.22.3 Bayer Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.22.4 Bayer Factor Xa Inhibitors Product Portfolio
8.22.5 Bayer Recent Developments
8.23 Apotex
8.23.1 Apotex Comapny Information
8.23.2 Apotex Business Overview
8.23.3 Apotex Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.23.4 Apotex Factor Xa Inhibitors Product Portfolio
8.23.5 Apotex Recent Developments
8.24 Accord Healthcare
8.24.1 Accord Healthcare Comapny Information
8.24.2 Accord Healthcare Business Overview
8.24.3 Accord Healthcare Factor Xa Inhibitors Sales, Value and Gross Margin (2020-2025)
8.24.4 Accord Healthcare Factor Xa Inhibitors Product Portfolio
8.24.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Factor Xa Inhibitors Value Chain Analysis
9.1.1 Factor Xa Inhibitors Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Factor Xa Inhibitors Sales Mode & Process
9.2 Factor Xa Inhibitors Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Factor Xa Inhibitors Distributors
9.2.3 Factor Xa Inhibitors Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.